This decision was the most recent in litigation involving challenges by eight generic companies to the patents protecting the statin Livalo.
Several of those defendants settled, and the US District Court entered judgment against the two remaining defendants, the generic drug manufacturers Amneal Pharmaceuticals LLP and Apotex, Inc. and Apotex Corp.
The US District Court issued two decisions one in April 2017 upholding the validity and infringement of US Patent No. 5,856,336 (the '336 patent), and the second in October 2017 upholding the validity and infringement of the '993 patent.
The '336 patent, which expires on December 25, 2020, covers pitavastatin calcium, the active ingredient in Livalo. The '993 patent, which expires on February 2, 2024, covers the polymorphic form of pitavastatin calcium in Livalo.
The plaintiffs, which included Kowa company, Ltd., Kowa Pharmaceuticals America, Inc., and Nissan Chemical Corp., prevailed on all issues in the US District Court decisions.
Amneal and Apotex both filed appeals to the US Court of Appeals for the Federal Circuit. Apotex subsequently abandoned its appeal and settled, agreeing to license to market its generic version of Livalo beginning on May 2, 2023, or earlier under certain circumstances.
Oral argument on the Amneal appeal was held on December 6, 2018, and the Federal Circuit entered its decision affirming the District Court's judgment on December 10, 2018.
As a result of the Federal Circuit decision, Amneal will be precluded from marketing its generic version of Livalo until after the expiration of the '993 patent in February 2024.
Kowa company, Ltd., Kowa Pharmaceuticals America, Inc., and Nissan Chemical Corp. are represented by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
Livalo is an HMG-CoA reductase inhibitor (statin). Livalo (pitavastatin) is indicated as an adjunctive therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides, and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hyperlipidemia or mixed dyslipidemia.
Kowa is a privately held, multinational company headquartered in Nagoya, Japan. Kowa Pharmaceuticals America, Inc., headquartered in Montgomery, AL, is focused primarily in the area of cardiometabolic diseases.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US